EPS Diluted (TTM) Chart

Historical EPS Diluted (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -11.76
March 31, 2026 -9.609
December 31, 2025 -8.234
September 30, 2025 -5.313
June 30, 2025 -5.198
March 31, 2025 -8.147
December 31, 2024 -8.561
September 30, 2024 -14.81
June 30, 2024 -36.34
March 31, 2024 -45.48
December 31, 2023 -488.56
September 30, 2023 -506.98
June 30, 2023 -517.24
March 31, 2023 -547.55
December 31, 2022 -141.98
September 30, 2022 -153.51
June 30, 2022 -156.23
March 31, 2022 -176.55
Date Value
December 31, 2021 -189.75
September 30, 2021 -234.06
June 30, 2021 -279.61
March 31, 2021 -314.57
December 31, 2020 -361.87
September 30, 2020 -414.98
June 30, 2020 -472.33
March 31, 2020 -538.77
December 31, 2019 -627.41
September 30, 2019 -653.12
June 30, 2019 -663.34
March 31, 2019 -650.65
December 31, 2018 -588.84
September 30, 2018 -572.26
June 30, 2018 -551.31
March 31, 2018 -399.15
December 31, 2017 -269.98
September 30, 2017 -128.68

EPS Diluted (TTM) Range, Past 5 Years

View EPS Diluted (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (TTM) Benchmarks

View EPS Diluted (TTM) Benchmarks
Start Trial
Q32 Bio, Inc. 3.343
IRulya Therapeutics, Inc. -125.60
Climb Bio, Inc. -0.6384
PepGen Inc. -1.306
Bridgebio Oncology Therapeutics, Inc. -1232.83